6:27 PM
 | 
May 18, 2016
 |  BC Extra  |  Clinical News

Data deluge for CDK4/CDK6 inhibitors in breast cancer

Abstracts released Wednesday ahead of next month's American Society of Clinical Oncology meeting showed strong survival and response rate data for cyclin dependent kinase 4 ( CDK4) and CDK6 inhibitors from Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY) to treat breast cancer. Separately, Novartis AG (NYSE:NVS; SIX:NOVN) said Wednesday that it would stop early a trial of its own CDK4/CDK6 inhibitor for breast cancer following a positive interim analysis.

As of Feb....

Read the full 378 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >